Leap Therapeutics (NASDAQ:LPTX)’s share price traded down 23.1% on Monday . The company traded as low as $6.94 and last traded at $7.49. 710,923 shares were traded during mid-day trading, an increase of 500% from the average session volume of 118,532 shares. The stock had previously closed at $9.74.
A number of equities analysts have weighed in on the company. Zacks Investment Research lowered Leap Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, January 19th. HC Wainwright initiated coverage on Leap Therapeutics in a research note on Thursday, April 12th. They set a “buy” rating and a $12.50 price target for the company. Finally, ValuEngine upgraded Leap Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, March 22nd.
The company has a market cap of $108.61, a PE ratio of -2.29 and a beta of -0.39.
Leap Therapeutics (NASDAQ:LPTX) last released its quarterly earnings results on Friday, February 23rd. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.77) by $0.12. equities analysts predict that Leap Therapeutics will post -2.37 earnings per share for the current fiscal year.
A hedge fund recently bought a new stake in Leap Therapeutics stock. Sabby Management LLC purchased a new stake in shares of Leap Therapeutics (NASDAQ:LPTX) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 89,350 shares of the company’s stock, valued at approximately $558,000. Sabby Management LLC owned 0.72% of Leap Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 2.77% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Leap Therapeutics (LPTX) Trading Down 23.1%” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/04/18/leap-therapeutics-lptx-trading-down-23-1.html.
About Leap Therapeutics
Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.